TCT 1195: Outcomes of Transcatheter Tricuspid Valve Replacement in Patients with Multivalvular Disease: Insights from the TRISCEND II Trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Edwards Lifesciences; Abbott; Bristol-Myers Squibb; Philips</li></ul>